Academic literature on the topic 'Glioma diagnosis'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Glioma diagnosis.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Glioma diagnosis"
Cherkasova, Olga, Yan Peng, Maria Konnikova, Yuri Kistenev, Chenjun Shi, Denis Vrazhnov, Oleg Shevelev, Evgeny Zavjalov, Sergei Kuznetsov, and Alexander Shkurinov. "Diagnosis of Glioma Molecular Markers by Terahertz Technologies." Photonics 8, no. 1 (January 16, 2021): 22. http://dx.doi.org/10.3390/photonics8010022.
Full textLee, Ian, Lisa Scarpace, Rachel Hunt, Kevin Nelson, Darshana Patil, Vineet Datta, Dadasaheb Akolkar, et al. "PATH-64. PROSPECTIVE, BLINDED PLASMA BASED ANALYSIS FOR DIAGNOSIS OF NEWLY DIAGNOSED GLIOMA." Neuro-Oncology 21, Supplement_6 (November 2019): vi157—vi158. http://dx.doi.org/10.1093/neuonc/noz175.659.
Full textNechipay, E. A., M. B. Dolgushin, A. I. Pronin, E. A. Kobyakova, and L. M. Fadeeva. "Dynamic Contrast Enhanced MRI in Glioma Diagnosis." Medical Visualization, no. 4 (August 28, 2017): 88–96. http://dx.doi.org/10.24835/1607-0763-2017-4-88-96.
Full textZhao, Shiguang. "BIOM-63. DIAGNOSIS AND PROGNOSTIC SIGNIFICANCE OF CIRCULATING miR-2276-5p IN PLASMA OF GLIOMA PATIENTS." Neuro-Oncology 22, Supplement_2 (November 2020): ii15. http://dx.doi.org/10.1093/neuonc/noaa215.060.
Full textYin, Luxin, and Liwei Zhang. "Correlation Between MRI Findings and Histological Diagnosis of Brainstem Glioma." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 40, no. 3 (May 2013): 348–54. http://dx.doi.org/10.1017/s0317167100014293.
Full textDu, Peng, Hongyi Chen, Kun Lv, and Daoying Geng. "A Survey of Radiomics in Precision Diagnosis and Treatment of Adult Gliomas." Journal of Clinical Medicine 11, no. 13 (June 30, 2022): 3802. http://dx.doi.org/10.3390/jcm11133802.
Full textOgawa, Tomoya, Keisuke Miyake, Takeshi Fujimori, Daisuke Ogawa, Masaki Okada, Tetsuhiro Hatakeyama, Masanobu Okauchi, Atsushi Shindo, Masahiko Kawanishi, and Takashi Tamiya. "NI-15 THE USEFULNESS OF PET IMAGING IN MOLECULAR DIAGNOSIS OF GLIOMA." Neuro-Oncology Advances 1, Supplement_2 (December 2019): ii28. http://dx.doi.org/10.1093/noajnl/vdz039.127.
Full textCheng, Chuandong, Ying Ji, Tiantian Han, Xiaomin Li, Yahui Huang, Weijie Sun, Guanghua Lu, Wanglong Deng, Ran Ding, and Fanfeng Bu. "MAPK pathway alteration may be a new integrated diagnosis term." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): e14022-e14022. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e14022.
Full textGalijasevic, Malik, Ruth Steiger, Stephanie Mangesius, Julian Mangesius, Johannes Kerschbaumer, Christian Franz Freyschlag, Nadja Gruber, Tanja Janjic, Elke Ruth Gizewski, and Astrid Ellen Grams. "Magnetic Resonance Spectroscopy in Diagnosis and Follow-Up of Gliomas: State-of-the-Art." Cancers 14, no. 13 (June 29, 2022): 3197. http://dx.doi.org/10.3390/cancers14133197.
Full textChaudhary, Reeta, Nishi Tandon, Andleeb Zehra, Jyoti Jaiswal, Nirupma Lal, and Bandhul Tiwari. "HIGH GRADE GLIOMA IN A 2 1/2 YEAR OLD: A CASE REPORT." Era's Journal of Medical Research 9, no. 1 (June 2022): 114–16. http://dx.doi.org/10.24041/ejmr2022.18.
Full textDissertations / Theses on the topic "Glioma diagnosis"
Marand, Sandie. "Identification et caractérisation fonctionnelle de protéines d'intérêt pour le diagnostic et la thérapie des tumeurs gliales." Université Joseph Fourier (Grenoble ; 1971-2015), 2009. http://www.theses.fr/2009GRE10043.
Full textGliomas, particulary glioblastoma, are public health problem because of their dark pronostic. Difficulties to classify and lack of anti-tumor therapy efficiency are due to ignorance about these tumors. To improve diagnosis and also to understand the process leading to glioma formation and so to find new treatment, we choose to study patient sera immuno-reactivity. So we discovered about a hundred of proteins which immune status change between normal and pathological condition. Identifying and studying these proteins, we highlight important mechanisms for cancer and define key targets for therapy. Among these proteins, we studied immuno-reactivity to ten which leads us to define two types of antigens : those which immune status changes with tumor appearance and those who change depending on the sensibility to treatment of the tumor. We then choose three of these proteins for detail analysis : eef1a1, crhsp24, mark3. These three antigens are overexpressed in gliomas. Expression inhibition by siRNA induced a diminution of tumoral cell proliferation, indicating that they are implicated in this mechanism regulation. This essential function makes these potential therapeutic targets. First tests of vaccination toward mark3 show that studying this antigen is of particular interest despite results are not those wished. We show here that auto-antibody associated to glioma presence can be found in sera. These antibodies clearly have diagnosis interest but also can have prognostic interest. Their biological analysis could lead to consider them like potential therapeutic targets
Di, Stefano Anna Luisa. "Molecular markers of gliomas : implications for diagnosis and new target therapies." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066015.
Full textThis work is devoted to the characterization of a specific oncogenic fusion between FGFR and TACC genes in gliomas. Overall, we screened 907 gliomas for FGFR3-TACC3 fusions. We found that FGFR3-TACC3 fusions exclusively affect IDH wild-type gliomas (3%), and are mutually exclusive with the EGFR amplification and the EGFR vIII variant, whereas it co-occurs with CDK4 amplification, MDM2 amplification and 10q loss. FGFR3–TACC3 fusions were associated with strong and homogeneous FGFR3 immunostaining. We show that FGFR3 immunostaining is a sensitive predictor of the presence of FGFR3-TACC3 fusions. FGFR3-TACC3 glioma patients had a longer overall survival than those patients with IDH wild-type glioma. We treated two patients with FGFR3–TACC3 rearrangements with a specific FGFR-TK inhibitor and we observed a clinical improvement in both and a minor response in one patient. In the second section, we developed a non-invasive diagnostic tool by 1H-magnetic resonance spectroscopy in IDH mutant gliomas. We optimized a uniquely different spectroscopy sequence called MEGA-PRESS for the detection of the oncometabolite 2-hydroxyglutarate (2 HG) that specifically accumulates in IDH mutant gliomas. We analysed a prospective cohort of 25 patients before surgery for suspected grade II and grade III gliomas and we assessed specificity and sensitivity, correlation with 2 HG concentrations in the tumor and associations with grade and genomic background. We found that MEGA-PRESS is highly specific (100%) and sensitive (80%) for the prediction of IDH mutation and correlated with 2 HG levels measured by gas chromatography-tandem mass spectrometry (GC-MS/MS) in frozen tissue
OLIVEIRA, ERICA A. de. "Desenvolvimento de radiotraçadores angiogênicos para diagnóstico de glioma: estudo em modelo animal." reponame:Repositório Institucional do IPEN, 2014. http://repositorio.ipen.br:8080/xmlui/handle/123456789/23233.
Full textMade available in DSpace on 2015-01-07T16:11:01Z (GMT). No. of bitstreams: 0
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Tese (Doutorado em Tecnologia Nuclear)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
FAPESP:11/12405-0
Farias, Alana Alves. "Análise da marcação de células da linhagem C6 de glioma com as lectinas vegetais CPL, WGA e Con A." reponame:Repositório Institucional da FIOCRUZ, 2015. https://www.arca.fiocruz.br/handle/icict/13028.
Full textApproved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-03-04T18:05:20Z (GMT) No. of bitstreams: 1 Alana Alves Farias Análise da marcação...2015.pdf: 1042656 bytes, checksum: 8c570ad74d5f6150c8fb9527f324b2d4 (MD5)
Made available in DSpace on 2016-03-04T18:05:20Z (GMT). No. of bitstreams: 1 Alana Alves Farias Análise da marcação...2015.pdf: 1042656 bytes, checksum: 8c570ad74d5f6150c8fb9527f324b2d4 (MD5) Previous issue date: 2015
Fundação Oswaldo Cruz, Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil
ntrodução e objetivos: O glioblastoma multiforme é um glioma de alto grau que apresenta um prognóstico ruim. O diagnóstico definitivo é estabelecido pela avaliação histológica, porém este pode apresentar conflitos na classificação, com isso surge à necessidade de ferramentas que auxiliem o patologista em sua análise. Atualmente, maior ênfase tem sido dada a alterações na glicosilação, pois estão associadas a neoplasias, e a descoberta da capacidade de lectinas em reconhecer tais alterações fez destas, ferramentas aplicáveis para o diagnóstico biomédico. Dessa forma, o objetivo deste trabalho é analisar a marcação das lectinas CpL, WGA e Con A em células da linhagem C6 e astrócitos. Métodos: As células foram cultivadas em condições estéreis, a 37ºC em atmosfera com 5 % de CO2 até atingirem confluência. Em seguida, foram lavadas com PBS e marcadas com as lectinas CpL, WGA e Con A numa concentração de 1 mg/ml, o controle negativo foi obtido com adição do carboidrato inibidor das lectinas (D-galactose, β-N-acetilglucosamina e glicose), respectivamente, numa concentração de 0,1 M. A incubação se deu por uma hora com proteção da luz, a análise foi realizada em microscópio de fluorescência. Para a quantificação em citometria de fluxo, as células foram marcadas obedecendo ao mesmo protocolo anterior, com exceção do tempo de incubação que se deu por 15 minutos. Posteriormente, as células foram lavadas, centrifugadas, transferidas para tubos e ressuspensas em PBS para a realização da leitura em citômetro. Resultados: A lectina CpL apresentou melhor marcação para os astrócitos, porém, ainda assim, mostra baixo desempenho comparado com as demais lectinas. Já a lectina WGA apresentou marcação eficiente tanto para astrócitos quanto para as células C6, esta última apresentou o dobro de emissão. Desta forma, é possível inferir que as lectinas CpL e WGA não são capazes de reconhecer diferenças importantes no perfil de glicoconjugados nas membranas das células C6 e dos astrócitos. Entretanto, a lectina Con A revelou marcação eficiente em relação às células C6 capaz de definir a forma celular, mostrando que há uma distribuição quase uniforme destes carboidratos ao longo da superfície da membrana, e ainda exibiu mediana de fluorescência cerca de 99 vezes superior em relação aos astrócitos. Assim, a Con A mostrou ser um marcador capaz de diferenciar as células da linhagem de glioma murino das células de cultura primária. Conclusão: Com base nestes resultados podemos inferir que a lectina Con A pode auxiliar numa identificação mais eficiente com possibilidade de um diagnóstico mais seguro.
Introduction and objectives: Glioblastoma multiforme is a high-grade glioma that has a poor prognosis. The definitive diagnosis is established by histological assessment. However, this can present conflicts in grading gliomas, which justifies new tools to assist the pathologist in his analysis. Currently, it is known that there are changes in glycosylation pattern of molecules associated with cancer, and the discovery of the ability of lectins to recognize these changes made these tools applicable for biomedical diagnosis. Thus, the aim of this study is to analyze the labelling of C6 and astrocyte lineage cells with fluorescent lectins CpL, WGA and Con A. Methods: The cells were cultured under sterile conditions at 37°C in an atmosphere with 5% CO2 until they reached confluence. They were then washed with PBS and labeled with CpL, WGA, or Con A lectins in a concentration of 1 mg/ml. Negative controls were incubated with the carbohydrate that competitively inhibits the reaction (D-galactose, β-N-acetylglucosamine and glucose, respectively), at a concentration of 0.1 M. The incubation occurred for one hour with protection from the light, the analysis was performed on a fluorescence microscope. For flow cytometry quantitation, cells were labeled following the same previous protocol, except that the incubation time was 15 minutes. Subsequently, the cells were washed, centrifuged, transferred to tubes and resuspended in PBS to carry out the reading on a cytometer. Results: The CpL lectin better labeled astrocytes. However, it showed a poor performance compared to other lectins. On the other hand, the WGA lectin efficiently marked both astrocytes and C6 cells; the latter presented the double emission compared to the former. Thus, it is possible to infer that the CpL and WGA lectins are not able to recognize important differences in the glycosylation profile in the membranes of C6 cells and astrocytes. However, the lectin Con A efficiently marked C6 cells, defining their morphology and showing that there is a nearly uniform distribution of glucose along the surface of the membrane, which was not observed in astrocytes. This also exhibited a median fluorescence about 99 times greater than that obtained for astrocytes. Thus, Con A showed to be a marker capable of differentiate cells of murine glioma lineage from primary astrocytes. Conclusion: Based on these results we can infer that the Con A lectin may be a tool for a more efficient identification of glioma cells in histopathological analysis.
Roller, Benjamin Thomas. "A nanoencapsulated visible dye for intraoperative delineation of brain tumor margins." Thesis, Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/42805.
Full textShirahata, Mitsuaki. "Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis." Kyoto University, 2008. http://hdl.handle.net/2433/124241.
Full textManita, Muftah. "The prognostic value of perfusion MRI in cerebral glioma." Thesis, University of Nottingham, 2012. http://eprints.nottingham.ac.uk/12776/.
Full textCiezka, Magdalena. "Improvement of Protocols for Brain Cancer Diagnosis and Therapy Response Monitoring Using Magnetic Resonance Based Molecular Imaging Strategies." Doctoral thesis, Universitat Autònoma de Barcelona, 2015. http://hdl.handle.net/10803/666281.
Full textBrain tumours account for less than 2% of all primary tumours, but are one of the most lethal cancers when “life lost” years are considered. Gliomas are the most prevalent type with a median life expectancy below 15 months for the high grade ones, such as glioblastomas (GBM). The most common non-invasive medical technique used for tumour diagnosis and therapy monitoring of brain tumours patients is Magnetic Resonance (MR), in the form of imaging (MRI) and spectroscopy (MRS) or spectroscopic imaging (MRSI). However, due to the ethical restrictions regarding the use of human patients for research study, the improvement of diagnostic and therapy follow-up protocols requires reliable models that mimic human disease. In this regard, mainly murine models are used and can be divided into the genetically engineered model (GEM) of spontaneous tumour development and the engrafted tumour model. In this thesis, a comprehensive MR characterization of two GEM colonies, namely S100β-v-erbB / inK4a-Arf (+/-) and GFAP-V12 HA-ras B8, was carried out. A low tumour penetrance found (16% and 1%, respectively) together with stochastic onset of GEM tumours, made them impractical for use in therapy response studies. The latter and the scarcity of low/intermediate grade brain tumour preclinical models motivated us to attempt to develop a transplantable glial tumour model of low/intermediate grade by disaggregation of a tumour mass from GEM. This should allow us to obtain an increased tumour incidence rate in comparison to GEM animals. Gliospheres from a grade III GEM tumour were successfully generated and displayed more than 60% penetrance, when stereotactically injected into the striatum of C57BL/6 mice. However, the application of freezing and cell culture protocols produced a progression to grade IV GBM, which made the developed transplantable model qualify as potential secondary GBM model in mice. Additionally, this transplantable model was widely characterized using MRI/MRS methods, as well as perturbation-enhanced MRSI (PE-MRSI) for a possible application in the future in therapy strategies and development of tumour therapy response detection classifiers. A restricted genetic evaluation of selected murine tumour models (i.e. GL261 tumours, GL261 cell line, GEM and GEM-derived tumours) was carried out using the Sanger method to check for a possible presence of particular driver mutations commonly occurring in gliomas (IDH1, IDH2 and p53). Finally, the work describes the strategy followed for longitudinal therapy studies follow-up and early response/relapse detection in preclinical brain tumours, through molecular imaging methods based in MRSI. GL261 (glioblastoma) tumour bearing mice were treated with temozolomide (TMZ), based on previously established protocols. The expected transient growth arrest (response to therapy) was detected by MRI. Animals subjected to therapy and control animals were followed up by MRSI and pattern recognition techniques (semi-supervised source extraction) were applied. The sources extracted from the region of interest were able to discriminate between GL261 tumours actively proliferating and tumours responding to therapy, based on their metabolome pattern changes recorded by MRSI. Colour-coded nosological images produced throughout and after the course of therapy allowed convenient tracking of response changes and differentiated the intratumoural heterogeneity of response, hinting the growth arrest and relapse, before changes in tumour volume were observed by MRI. The methodology was validated with histopathological analysis and calculation of proliferation and apoptotic rates and mitotic index.
Billard, Pauline. "Maintenance télomérique : intérêt dans le diagnostic des gliomes en lien avec le métabolisme mitochondrial." Thesis, Lyon, 2021. http://www.theses.fr/2021LYSE1303.
Full textThe Shelterin complex, made of 6 proteins (POT1 / TRF1 / TRF2 / TIN2 / RAP1 and ACD) plays a major role in telomeres. Thus, it allows the protection of the telomeric single-stranded end by the formation of the D-loop, the regulation of DNA damage signaling pathways; it participates in telomere replication and controls the accessibility and processivity of the telomerase, the unique enzyme allowing telomere lengthening. During this thesis, my work was organized in 2 main axes, the first, fundamental, was interested in the extra-telomeric effects of the ACD protein (also called TPP1). The second, more transversal, focused on the processes of telomere maintenance in gliomas. Concerning the first aspect, it is now known that the ACD protein makes the link between TIN2 and TERT (catalytic subunit of telomerase) in the telomeres. These two proteins can also partially localize to the mitochondria and then have various effects on mitochondrial metabolism, on the oxidative stress regulation or on the mitophagy process. Thus, and following in silico predictions of a putative MTS for ACD, we hypothesized that ACD could be the missing partner of TIN2 and TERT in the mitochondria. In this case, it then remained to identify its mitochondrial functions. After demonstrating the partial localization of ACD in the mitochondria by different methods, we were able to demonstrate its influence in the protection against oxidative stress. Thus overexpression of ACD reduces secondary production of mitochondrial oxygen radicals and loss of mitochondrial DNA. Oxidative stress causing reduction of ACD mitochondrial foci. Secondly, we looked at the telomere maintenance mechanisms (TMM) that cancer cells acquire in order to override replicative senescence. In this sense, tumors can reactivate telomerase (95% of cancer) or use an alternative process (ALT) based on homologous recombination (5% of cancer). In the case of gliomas, up to 25% of tumors use the ALT process, associated with the loss of ATRX, the other gliomas use telomerase and typically have a mutation of the TERT promoter (TERTmt). These two molecular markers also have diagnostic and prognostic value and are part of the WHO histo-molecular classification criteria. But, 4 to 28% of gliomas (depending on the subtypes) do not have an ATRX alteration or TERT mutation suggesting activation of one of the TMM by other alterations or even other pathways. In this sense, we have developed a test measuring the true TMM based on the detection of c-circles (a marker of ALT) and proposed a patented algorithm (TeloDiag) taking into account this TMM, IDH mutations and the histological grading. The TeloDiag makes it possible to re-classify 38% of atypical gliomas (at the molecular level). It generated a new category of high grade IDHwt and ALT + tumors, not found in the WHO classification and showing a tendency for a better prognosis than IDHwt glioblastomas (TERTmt). Finally, we provided the proof of concept of the feasibility of this circulating test for IDHmt astrocytomas
Taylor, G. Scott. "Design and Development of Oligonucleotide Microarrays and their Application in Diagnostic and Prognostic Estimation of Human Gliomas." VCU Scholars Compass, 2006. http://scholarscompass.vcu.edu/etd/1459.
Full textBooks on the topic "Glioma diagnosis"
Gliomas. Berlin: Springer, 2009.
Find full textP, Rock Jack, ed. The practical management of low-grade primary brain tumors. Philadelphia: Lippincott Williams & Wilkins, 1999.
Find full textScarabino, Tommaso. Imaging Gliomas After Treatment: A Case-based Atlas. Milano: Springer Milan, 2012.
Find full textGlioma. Springer Verlag, 1991.
Find full textKarim, Abul Bashr Mohammed Fazlul. and Laws Edward R, eds. Glioma: Principles and practice in neuro-oncology. Berlin: Springer-Verlag, 1991.
Find full textBarnett, Gene H. High-grade Gliomas: Diagnosis and Treatment. Humana P.,U.S., 2006.
Find full textBarnett, Gene H. High-Grade Gliomas: Diagnosis and Treatment (Current Clinical Oncology). Humana Press, 2006.
Find full textH, Barnett Gene, ed. High-grade gliomas: Diagnosis and treatment. Totowa, N.J: Humana Press, 2007.
Find full textHigh-Grade Gliomas: Diagnosis and Treatment. Humana, 2010.
Find full textFriedman, Allan H., Roger E. McLendon, Darell D. Bigner, John H. Sampson, and Henry S. Friedman. Duke Glioma Handbook: Pathology, Diagnosis, and Management. Cambridge University Press, 2016.
Find full textBook chapters on the topic "Glioma diagnosis"
Stam, F. C. "The Problems of Pathological Diagnosis." In Glioma, 17–36. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-84127-9_2.
Full textNasrallah, MacLean P. "Glioma Diagnosis and Classification: Illuminating the Gold Standard." In Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, 3–10. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72084-1_1.
Full textLi, Yuexiang, and Linlin Shen. "Deep Learning Based Multimodal Brain Tumor Diagnosis." In Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, 149–58. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75238-9_13.
Full textKawai, Nobuyuki, Yoshihiro Nishiyama, and Takashi Tamiya. "Newly Diagnosed Glioma: Diagnosis Using Positron Emission Tomography with Methionine and Fluorothymidine." In Tumors of the Central Nervous System, Volume 2, 103–12. Dordrecht: Springer Netherlands, 2011. http://dx.doi.org/10.1007/978-94-007-0618-7_12.
Full textWestermark, B., M. Nistér, and C. H. Heldin. "Oncogenes, Growth Factors and the Pathogenesis of Human Glioma: The 1986 Engelhardt Lecture." In Brain Oncology Biology, diagnosis and therapy, 7–13. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_2.
Full textNakamura, Osamu, and Masao Iwamori. "Glycolipid in Human Glioma: Detection with Specific Antibodies and Its Application for Diagnosis of Gliomas." In Biological Aspects of Brain Tumors, 421–24. Tokyo: Springer Japan, 1991. http://dx.doi.org/10.1007/978-4-431-68150-2_59.
Full textBradford, R., J. L. Darling, and D. G. T. Thomas. "Heterogeneity in Chemosensitivity and Acquisition of Drug Resistance in a Murine Model of Glioma." In Brain Oncology Biology, diagnosis and therapy, 363–67. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_65.
Full textYin, Baocai, Hu Cheng, Fengyan Wang, and Zengfu Wang. "CA-Net: Collaborative Attention Network for Multi-modal Diagnosis of Gliomas." In Brainlesion: Glioma, Multiple Sclerosis, Stroke and Traumatic Brain Injuries, 52–62. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-08999-2_4.
Full textBateman, D. E., J. R. McDermott, D. Hughes, and J. A. Edwardson. "The Selective Release of Polypeptides from Human Glioma Cell Cultures and their Modification by Dexamethasone." In Brain Oncology Biology, diagnosis and therapy, 143–48. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3347-7_25.
Full textAlbert, Nathalie L., Bogdana Suchorska, Adrien Holzgreve, and Marcus Unterrainer. "Case 25: Primary Diagnosis of an Isocitrate Dehydrogenase (IDH) Wild-Type Glioma." In Clinical Nuclear Medicine in Neurology, 125–28. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-83598-9_25.
Full textConference papers on the topic "Glioma diagnosis"
Shboul, Zeina, and Khan Iftekharuddin. "Prediction of low-grade glioma progression using MR imaging." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Kensaku Mori. SPIE, 2019. http://dx.doi.org/10.1117/12.2512620.
Full textGates, Evan, Jonathan Lin, Jeffrey S. Weinberg, Sujit S. Prabhu, Jackson Hamilton, John D. Hazle, Gregory N. Fuller, Veera Baladandayuthapani, David Fuentes, and Dawid Schellingerhout. "Advanced magnetic resonance imaging based algorithm for local grading of glioma." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Maciej A. Mazurowski. SPIE, 2020. http://dx.doi.org/10.1117/12.2549607.
Full textJuarez Chambi, Ronald, Carmen Kut, Kaisorn L. Chaichana, Alfredo Quiñones-Hinojosa, Xingde Li, and Javier Jo. "Neural networks for in situ detection of glioma infiltration using optical coherence tomography." In Computer-Aided Diagnosis, edited by Horst K. Hahn and Maciej A. Mazurowski. SPIE, 2020. http://dx.doi.org/10.1117/12.2549612.
Full textKorfiatis, Panagiotis, Timothy L. Kline, and Bradley J. Erickson. "Evaluation of a deep learning architecture for MR imaging prediction of ATRX in glioma patients." In Computer-Aided Diagnosis, edited by Kensaku Mori and Nicholas Petrick. SPIE, 2018. http://dx.doi.org/10.1117/12.2293538.
Full textShi, Hong-yan, Xiao-qiang Wu, Li-hua Wang, and Li Li. "Study on MRI and CT Combined Diagnosis Technology Application in Brain Glioma Diagnosis." In 2017 7th International Conference on Applied Science, Engineering and Technology (ICASET 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/icaset-17.2017.15.
Full textZhou, Yan, Binlin Wu, Cheng-hui Liu, Xinguang Yu, Gangge Cheng, Kai Wang, Chunyuan Zhang, Lingyan Shi, and Robert R. Alfano. "Diagnosis of glioma brain cancer using visible resonance Raman spectroscopy." In Frontiers in Optics. Washington, D.C.: OSA, 2018. http://dx.doi.org/10.1364/fio.2018.jw4a.3.
Full textZhou, Yan, Cheng-Hui Liu, Ke Zhu, Binlin Wu, Xinguang Yu, Gangge Cheng, Mingyue Zhao, et al. "Human brain glioma grading using label free laser-induced fluorescence spectroscopy." In Optical Biopsy XVII: Toward Real-Time Spectroscopic Imaging and Diagnosis, edited by Robert R. Alfano, Stavros G. Demos, and Angela B. Seddon. SPIE, 2019. http://dx.doi.org/10.1117/12.2511687.
Full textPalande, V., D. Raviv-Shay, and M. Frenkel-Morgenstern. "PO-301 Diagnosis of glioma tumours using circulating cell-free DNA." In Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.332.
Full textNjeh, Ines, Lamia Sallemi, Mohamed Ben Slima, Ahmed Ben Hamida, Stephane Lehericy, and Damien Galanaud. "A computer aided diagnosis ‘CAD’ for brain glioma exploration." In 2014 International Conference on Advanced Technologies for Signal and Image Processing (ATSIP). IEEE, 2014. http://dx.doi.org/10.1109/atsip.2014.6834615.
Full textAmaya-Rodriguez, I., L. Duran-Lopez, F. Luna-Perejon, J. Civit-Masot, J. Dominguez-Morales, S. Vicente, A. Civit, D. Cascado, and A. Linares-Barranco. "Glioma Diagnosis Aid through CNNs and Fuzzy-C Means for MRI." In 11th International Conference on Neural Computation Theory and Applications. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0008494005280535.
Full textReports on the topic "Glioma diagnosis"
Zhang, Hui-Mei, Xiao-Bing Huo, Hua-Long Wang, and Chen Wang. Recurrent glioma and radiation necrosis: a meta-analysis of MRI diagnosis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0028.
Full textChen, Qian, Yuhua Hu, Haihua Zhan, and Yawei He. The diagnostic value of miR-221/222 in glioma : a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2021. http://dx.doi.org/10.37766/inplasy2021.3.0064.
Full textHua, Rong, Yi-Bing Shi, Yu-Fei Fu, and Chen Wang. Diagnostic performance of dynamic susceptibility contrast-enhanced perfusion-weighted imaging in differentiating recurrence from radiation injury in postoperative glioma: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0101.
Full textHuo, Zhenyu, Feifei Chong, Lingyu Yin, Zongliang Lu, Jie Liu, and Hongxia Xu. Accuracy of the GLIM criteria for diagnosing malnutrition: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0061.
Full text